Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons
- 1 January 2009
- journal article
- Published by Wiley in Transfusion
- Vol. 49 (1) , 64-74
Abstract
Pathogen reduction methods have the potential to modify blood components, resulting in immunologic reactions or compromised blood components. This study evaluated the hypothesis that there is no immune response to riboflavin-and-ultraviolet [UV]-light-treated red blood cells (RBCs), as observed by serology and by survival of RBCs in circulation. Three baboons were in each treatment group: 1) untreated (negative control), 2) quinacrine mustard (QM)-treated (positive control), and 3) riboflavin-and-UV light-treated (test group) RBCs. In the immunization phase, autologous test or control RBCs were injected subcutaneously on Days 0, 21, 42, and 49. Plasma samples from these days were tested against test or control RBCs by flow cytometry and standard serology. On Day 56, autologous (51)Cr-labeled test or control RBCs were injected. Blood samples were taken over 21 days after injection to determine RBC survival (t(1/2)). Untreated and riboflavin-and-UV-light-treated RBCs showed no evidence of significant immunoglobulin G (IgG) binding after incubation with autologous plasma. RBC-bound IgG was detected on QM-treated RBCs after incubation with autologous plasma. This antibody was inhibited by QM, as demonstrated by a hapten inhibition study. t(1/2) values for the untreated and riboflavin-and-UV-light-treated RBCs were 7.3 +/- 0.8 and 7.5 +/- 1.7 days, respectively; the t(1/2) value for QM-treated RBCs was 2.3 +/- 2.9 days. Treatment with riboflavin and UV light did not render RBCs immunogenic. Positive controls indicated that immunization promoted an immune response. In the (51)Cr-labeled RBC survival phase of the study, riboflavin-and-UV-light-treated RBCs exhibited behavior similar to negative control RBCs. Detrimental immunologic or functional side effects were not observed.Keywords
This publication has 27 references indexed in Scilit:
- Pathogen inactivation: making decisions about new technologiesTransfusion, 2007
- Pathogen-reduction systems for blood components: The current position and future trendsTransfusion and Apheresis Science, 2006
- Viability of red cells prepared with S‐303 pathogen inactivation treatmentTransfusion, 2006
- Red blood cell pathogen reduction: in search of serological agnosticismISBT Science Series, 2006
- Therapeutic efficacy and safety of red blood cells treated with a chemical process (S‐303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patientsTransfusion, 2005
- Broad‐spectrum virus reduction in red cell concentrates using INACTINE™ PEN110 chemistryVox Sanguinis, 2002
- Volume of RBCs, 24‐ and 48‐hour posttransfusion survivals, and the lifespan of 51Cr and biotin‐X‐N‐hydroxysuccinimide (NHS)‐labeled autologous baboon RBCs: effect of the anticoagulant and blood pH on 51Cr and biotin‐X‐NHS elution in vivoTransfusion, 2002
- Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitizationTransfusion, 1994
- Photo-induced riboflavin binding to the tryptophan residues of bovine and human serum albuminsRadiation and Environmental Biophysics, 1991
- Plasma Protein Binding of Riboflavin and Riboflavin-5′-phosphate in ManJournal of Pharmaceutical Sciences, 1969